Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Pan-Cancer Single-Cell Atlas to Evaluate Tumor Identity, Cell Line Concordance, and Dependency Mapping

ABSTRACT: Bulk RNA sequencing enables pan-cancer transcriptional analyses, but obscures cancer cell-specific programs due to admixture with nonmalignant cells, limiting direct comparison between experimental models and human tumors. Single-cell RNA sequencing (scRNA-seq) overcomes these limitations, yet biological interpretability of public datasets is often compromised by variable data quality, inconsistent annotation, and atlas-scale aggregation strategies that favor data volume over biological coherence. We therefore developed a stringent integration framework that prioritizes representative malignant transcriptional states. Using Mahalanobis distance-based selection in batch-corrected latent space, we constructed a pan-cancer atlas of 135,441 high-quality malignant cells from 494 samples spanning 36 adult and pediatric cancer types. Atlas-derived signatures were used to assess tumor–cell line concordance and project ElasticNet models trained on DepMap CRISPR screens to infer cancer-specific gene dependencies. Together, the scTumor Atlas provides a scalable framework for tumor identity inference, cancer cell line benchmarking, and systematic identification of genetic vulnerabilities.

ORGANISM(S): Homo sapiens

PROVIDER: GSE319327 | GEO | 2026/07/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

COPG1 Is a Selectively Essential Regulator of Cancer Progression and Chemoresistance: A Comprehensive Pan-Cancer Study

Project description:The coatomer complex, a key regulator of intracellular vesicular transport, has recently been implicated in cancer progression, yet a comprehensive pan-cancer analysis of its subunits has been lacking. Here, we systematically profiled genetic alterations, expression patterns, prognostic relevance, and functional dependencies of all COPI and COPII coatomer subunits across 33 cancer types using more than 10,000 tumor samples from The Cancer Genome Atlas (TCGA), complemented by functional perturbation data from CRISPR (n = 1,178) and RNAi (n = 707) screens in DepMap. Gene amplification—most notably of COPB2—was the most frequent alteration and was associated with poor survival in bladder and esophageal cancers. Mutations in COPA and SEC31A also demonstrated prognostic significance in endometrial carcinoma. Expression analyses revealed broad upregulation of coatomer genes across cancer types, with COPG1 and COPB1 emerging as strong risk-associated genes (HR > 2). Integrative functional dependency analyses further identified COPG1 and COPE as selectively essential in multiple cancer contexts, with COPG1 loss notably linked to increased drug sensitivity. Functional validation in hepatocellular carcinoma (HCC) showed that COPG1 knockdown impaired malignant phenotypes and reduced tumorigenicity in vivo. Mechanistically, COPG1 depletion induced Golgi disruption and ER stress, increased ROS production, and suppressed PI3K–AKT signaling. Moreover, COPG1 knockdown sensitized HCC cells to sorafenib and doxorubicin, whereas COPG1 overexpression conferred resistance. Collectively, our pan-cancer analysis reveals context-dependent roles of coatomer subunits and identifies COPG1 as a novel oncogenic driver and potential therapeutic target in HCC, mediating chemoresistance through redox modulation and PI3K–AKT pathway inhibition.

2025-11-27 | GSE311074 | GEO

Targeted metabolomics of pancancer brain metastasis

Project description: The molecular heterogeneity of brain metastases hampers therapeutic development for cures. To address this unmet and urgent need, we constructed a comprehensive multi-omic, single cell, and spatially resolved atlas of 1,032 pan-cancer brain metastases, identifying four robust molecular subtypes with distinct biological programs and clinical associations. These brain metastases subtypes (BrMS) are defined by unique biological states: neural-like (BrMS1), metabolic (BrMS3), highly proliferative/immune-excluded (BrMS4), and an immune-infiltrated (BrMS2) state featuring a coordinated epithelial-mesenchymal transition program. Patient-derived organoids coupled with targeted drug screening indicate subtype-specific molecular dependencies and putative targets, notably mTOR signaling activation in BrMS3 and CDK4/6 axis activation in BrMS4, while BrMS1 and BrMS2 display distinct radiobiologic and immunologic signatures. This atlas provides a rigorous classification framework of BrMs and offers insights into subtype-specific molecular vulnerabilities.

2025-12-22 | MTBLS13554 | MetaboLights

The Cancer Dependency Map (DepMap)

Project description:The Cancer Dependency Map (DepMap)

| PRJNA1027967 | ENA

The Cancer Dependency Map (DepMap)

Project description:The Cancer Dependency Map (DepMap)

| PRJNA1027968 | ENA

Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response

Project description:Tau (MAPT) is a microtubule-associated protein causing frequent neurodegenerative diseases or inherited frontotemporal lobar degenerations. Emerging evidence for non-canonical functions of Tau in DNA protection and P53 regulation suggests its involvement in cancer. Indeed, Tau expression correlates with cancer-specific survival or response to microtubule therapeutics. These data may imply common molecular pathways involved in the pathogenesis of neurodegenerative disorders and cancer. To bring new evidence that Tau represents a key protein in cancer, we present an in silico pan-cancer analysis of MAPT transcriptomic profile in over 11000 clinical samples and over 1300 pre-clinical samples provided by the TCGA and the DEPMAP datasets respectively. We completed this analysis by exploring a possible interplay of MAPT with wild-type or mutated P53. Then, we calculated the impact of MAPT expression on clinical outcome and drug response. Overall, the results support a relevant role of the MAPT gene in several cancer types, although the contribution of Tau to cancer appears to very much depend on the cellular context.

2022-11-27 | E-MTAB-8166 | biostudies-arrayexpress

Single-cell multimodal profiling of pan-cancer cell lines uncovers gene regulatory principles underlying intrinsic cell states and environmental features

Project description:Cancer arises from somatic mutations whose effects are executed through dysregulated gene-regulatory programs that reshape chromatin, transcription, and malignant phenotypes. To uncover gene regulatory principles underlying heterogeneous cancer cell states and their linked environmental features, here we present a pan-cancer single-cell, multi-omic atlas of human cancer cell lines, including a compendium of 240,957 transcriptomes and 223,347 chromatin-accessibility profiles from primary cancers spanning 20 tumor types. We revealed extensive pan-cancer cell-state heterogeneity, core gene-regulatory networks, and consensus epithelial–mesenchymal transition (EMT) trajectories that transcend tissue of origin and are governed by conserved epigenomic and transcriptomic features. In addition, our copy-number variation analysis implicated transcription factor amplification, followed by hyperactive downstream regulation, as a major driver of malignant states. Further focused analysis of acral versus cutaneous melanoma cell lines uncovers a universal inflammation-suppressive program in acral melanoma versus an inflamed regulatory landscape in cutaneous melanoma, highlighting the JAK–STAT axis as a key discriminator. Finally, by integrating single-cell and bulk datasets across models and patient cohorts, we revealed tumor–microenvironment co-adaptation in vivo, and this was associated with immunotherapy responsiveness.

2026-03-02 | GSE311521 | GEO

Pan-cancer proteomic map of 949 human cell lines (ProCan-DepMapSanger)

Project description:This pan-cancer cell line proteomic atlas comprises proteomic data acquired by data independent acquisition (specifically, SWATH) mass spectrometry for 949 cancer cell lines. Cell lines were processed in technical triplicate, with duplicates acquired on different mass spectrometers, alongside HEK293T cell line control samples processed across the experimental period. For further details, refer to the publication that accompanies this data deposition.

2022-07-13 | PXD030304 | Pride

Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment

Project description:Transcriptional heterogeneity among malignant cells of a tumor has been studied in individual cancer types and shown to be organized into cancer cell states; however, it remains unclear to what extent these states span tumor types, constituting general features of cancer. Here, we perform a pan-cancer single-cell RNA-Seq analysis across 15 cancer types and identify a catalog of gene modules whose expression defines recurrent cancer cell states including ‘stress’, ‘interferon response’, ‘epithelial-mesenchymal transition’, ‘metal response’, ‘basal’ and ‘ciliated’. Spatial transcriptomic analysis linked the interferon response in cancer cells to T cells and macrophages in the tumor microenvironment. Using mouse models, we further found that induction of the interferon response module varies by tumor location and is diminished upon elimination of lymphocytes. Our work provides a framework for studying how cancer cell states interact with the tumor microenvironment to form organized systems capable of immune evasion, drug resistance, and metastasis.

2022-08-05 | GSE203612 | GEO

RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass and molecular pathway cancer diagnostics

Project description:We report RNA-sequencing data of 283 blood platelet samples, including 228 tumor-educated platelet (TEP) samples collected from patients with six different malignant tumors (non-small cell lung cancer, colorectal cancer, pancreatic cancer, glioblastoma, breast cancer and hepatobiliary carcinomas). In addition, we report RNA-sequencing data of blood platelets isolated from 55 healthy individuals. This dataset highlights the ability of TEP RNA-based 'liquid biopsies' in patients with several types with cancer, including the ability for pan-cancer, multiclass cancer and companion diagnostics. Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing EDTA anti-coagulant by standard centrifugation. Total RNA was extracted from the platelet pellet, subjected to cDNA synthesis and SMARTer amplification, fragmented by Covaris shearing, and prepared for sequencing using the Truseq Nano DNA Sample Preparation Kit. Subsequently, pooled sample libraries were sequenced on the Illumina Hiseq 2500 platform. All steps were quality-controlled using Bioanalyzer 2100 with RNA 6000 Picochip, DNA 7500 and DNA High Sensitivity chips measurements. For further downstream analyses, reads were quality-controlled using Trimmomatic, mapped to the human reference genome using STAR, and intron-spanning reads were summarized using HTseq. The processed data includes 285 samples (columns) and 57736 ensemble gene ids (rows). The supplementary data file (TEP_data_matrix.txt) contains the intron-spanning read counts, after data summarization by HTseq.

2015-10-30 | E-GEOD-68086 | biostudies-arrayexpress

The Pan-Cancer Proteome Atlas, a mass spectrometry-based landscape for understanding tumor biology and discovering biomarkers and therapeutic targets

Project description:Next-generation quantitative proteomics based on data-independent acquisition mass spectrometry (DIA-MS) enables large-scale sample profiling, a necessity for (pre)clinical studies with heterogeneous samples. To date, most cancer protein profiling studies have focussed on a single cancer type. Here we report on The PanCancer Proteome Atlas (TPCPA) project, a multi-laboratory cancer proteome profiling effort based on DIA-MS. We generated a pan-cancer proteome landscape consisting of 1129 samples including 999 primary cancers representing 22 cancer types, to better understand cancer biology and to identify core and cancer type-enriched molecular therapeutic targets and biomarkers.

2025-05-30 | PXD054790 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data